Jun 17, 2020
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
Jun 16, 2020
Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020
Jun 16, 2020
CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company
Jun 02, 2020
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
May 29, 2020
Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)
May 29, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 20, 2020
Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
May 20, 2020
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
May 18, 2020
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
May 18, 2020
CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18.2-CAR-T Cells
May 18, 2020
WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform
May 15, 2020
GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR) Meeting II
May 13, 2020
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 13, 2020
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
May 07, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
May 06, 2020
Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy
May 04, 2020
Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020
Apr 29, 2020
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
Apr 28, 2020
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR(TM) GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
Apr 27, 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma